Steve Jobs’ son says the GLP-1 revolution could help fight cancer: ‘Some of the most important drugs we’ve ever actually seen come to market’

Reed Jobs, son of the late Steve Jobs, believes that GLP-1s, hailed as "some of the most impactful drugs we've ever seen," could play a significant role in fighting cancer. After his father's pancreatic cancer diagnosis in 2003, Reed delved into cancer research at Stanford and later founded Yosemite, a venture capital firm focused on oncology.

He expressed excitement over experimental cancer vaccines but believes GLP-1s deserve more attention. These drugs, which primarily target obesity, can prevent cancer by reducing obesity risk, which is linked to 13 types of cancer according to the CDC. Reed stated that GLP-1s could also benefit those struggling with obesity, cardiovascular disease, and other health issues.

Given that obesity is responsible for 40% of all cancer diagnoses in the U.S., Reed compared obesity to smoking, emphasizing that prolonged exposure to either risk factor significantly increases the likelihood of developing certain cancers. He acknowledged the drawbacks of GLP-1s, such as muscle loss, but regarded their growing popularity as the most significant biotechnology breakthrough in the past three years.

Reed also drew a parallel between managing HIV with medication and treating cancer, expressing hope that cancer treatment could become similarly manageable.